Cargando…

Infectious complications of CAR T-cell therapy: a clinical update

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary treatment modality used to treat haematological malignancies. Lymphocytes are engineered to produce CARs directed towards tumour cell antigens. Clinical trials have demonstrated impressive malignancy-related outcomes. Unfortunately, n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stewart, Adam G., Henden, Andrea S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388233/ https://www.ncbi.nlm.nih.gov/pubmed/34457269 http://dx.doi.org/10.1177/20499361211036773

Ejemplares similares

Neurological updates: neurological complications of CAR-T therapy
por: Tallantyre, Emma C., et al.
Publicado: (2020)

Clinical development of CAR T cell therapy in China: 2020 update
por: Wei, Jianshu, et al.
Publicado: (2020)

Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
por: Asmamaw Dejenie, Tadesse, et al.
Publicado: (2022)

925. Infectious Complications Following Chimeric Antigen Receptor (CAR) T-cell Therapy
por: Trottier, Caitlin, et al.
Publicado: (2021)

Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T
por: Crees, Zachary D., et al.
Publicado: (2021)

Complications after CD19+ CAR T-Cell Therapy
por: Penack, Olaf, et al.
Publicado: (2020)

2694. Infectious Complications in CAR-T Cell Therapy Recipients: A Systematic Review and Meta-Analysis
por: Banegas, Marcela, et al.
Publicado: (2023)

1105. The Burden of Infections Prior to Chimeric Antigen Receptor (CAR) Modified T-cell Therapy Predicts Post-CAR T-cell Infectious Complications
por: Garner, Will, et al.
Publicado: (2020)

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
por: Kambhampati, Swetha, et al.
Publicado: (2022)

Beyond CAR T-Cell Therapy: Continued Monitoring and Management of Complications
por: Reiser, Victoria
Publicado: (2020)

Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy
por: Maron, Gabriela M., et al.
Publicado: (2022)

Recent updates on CAR T clinical trials for multiple myeloma
por: Lin, Quande, et al.
Publicado: (2019)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Infectious optic neuropathies: a clinical update
por: Kahloun, Rim, et al.
Publicado: (2015)

CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases
por: Seif, Michelle, et al.
Publicado: (2019)

Dasatinib for treatment of CAR T-cell therapy-related complications
por: Baur, Katharina, et al.
Publicado: (2022)

Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature
por: Mercadal, Santiago, et al.
Publicado: (2023)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Donor T cells for CAR T cell therapy
por: Tang, Tiffany C. Y., et al.
Publicado: (2022)

Clinical manufacturing of CAR T cells: foundation of a promising therapy
por: Wang, Xiuyan, et al.
Publicado: (2016)

Infectious Complications of Cancer Therapy
por: Safdar, Nasia, et al.
Publicado: (2006)

Applying a clinical lens to animal models of CAR-T cell therapies
por: Duncan, Brynn B., et al.
Publicado: (2022)

Indoor Air Pollution in Cars: An Update on Novel Insights
por: Zulauf, Nicole, et al.
Publicado: (2019)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors
por: Boccalatte, Francesco, et al.
Publicado: (2022)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

New development in CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2017)

Global Manufacturing of CAR T Cell Therapy
por: Levine, Bruce L., et al.
Publicado: (2016)

CAR-T Cell Therapy and the Gut Microbiota
por: Asokan, Sahana, et al.
Publicado: (2023)

CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours
por: Tang, Hiu Kwan Carolyn, et al.
Publicado: (2023)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas
por: Kyriakidis, Ioannis, et al.
Publicado: (2022)

Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies
por: Liu, Qianzhen, et al.
Publicado: (2022)

83. Infectious Outcomes of CAR T-cell Therapy: Longitudinal Follow Up and Risk Stratification
por: Czapka, Michael, et al.
Publicado: (2022)

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

CAR T cell therapy in solid tumors: A review of current clinical trials
por: Patel, Urvi, et al.
Publicado: (2021)

CAR-T Cell Therapy: From the Shop to Cancer Therapy
por: Uscanga-Palomeque, Ashanti Concepción, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e7i686i8udg4cad113guoc4ihn